Elagolix: a promising oral GnRH antagonist for endometriosis-associated pain

Condition tags

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (8)

• Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study via openalex
• Elagolix, an Oral GnRH Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis: Effects on Bone Mineral Density via openalex
• Elagolix Treatment for Endometriosis-Associated Pain: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study via openalex
• Endometriosis via openalex
• Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix via openalex
• Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist via openalex
• W2085320423 via openalex
• W2610244466 via openalex

Cited by (6)

• Updates in Endometriosis Management 2024
• Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women 2021
• Extra‐pelvic endometriosis: A review 2020
• Endometrial Immune-Inflammatory Gene Signatures in Endometriosis 2019
• Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment 2018
• Elagolix for endometriosis: all that glitters is not gold 2018

Source provenance

europepmc

last seen: 2026-06-04T01:30:01.192114+00:00

openalex

last seen: 2026-06-04T00:00:01.174412+00:00

pubmed

last seen: 2026-05-13T22:20:07.505861+00:00